INR 29.0
(-0.82%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 541.92 Million INR | 18.92% |
2022 | 455.69 Million INR | -11.15% |
2021 | 512.86 Million INR | 4.79% |
2020 | 489.43 Million INR | -45.93% |
2019 | 905.23 Million INR | -40.91% |
2018 | 1.53 Billion INR | -9.59% |
2017 | 1.69 Billion INR | 10.92% |
2016 | 1.52 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -966.76 Million INR | -278.39% |
2023 Q2 | 526.29 Million INR | 0.0% |
2023 Q4 | 541.92 Million INR | 0.0% |
2023 FY | 541.92 Million INR | 18.92% |
2023 Q3 | - INR | -100.0% |
2023 Q1 | - INR | -100.0% |
2022 Q2 | 507.11 Million INR | 0.0% |
2022 FY | 455.69 Million INR | -11.15% |
2022 Q1 | - INR | -100.0% |
2022 Q3 | - INR | -100.0% |
2022 Q4 | 455.69 Million INR | 0.0% |
2021 Q2 | 531.28 Million INR | 0.0% |
2021 FY | 512.86 Million INR | 4.79% |
2021 Q3 | - INR | -100.0% |
2021 Q4 | 512.86 Million INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2020 Q4 | 489.43 Million INR | 0.0% |
2020 Q1 | - INR | -100.0% |
2020 Q3 | - INR | -100.0% |
2020 Q2 | 473.62 Million INR | 0.0% |
2020 FY | 489.43 Million INR | -45.93% |
2019 Q2 | 1.32 Billion INR | 0.0% |
2019 Q3 | - INR | -100.0% |
2019 FY | 905.23 Million INR | -40.91% |
2019 Q4 | 905.23 Million INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2018 Q4 | 1.53 Billion INR | 0.0% |
2018 FY | 1.53 Billion INR | -9.59% |
2018 Q2 | 1.51 Billion INR | 0.0% |
2018 Q1 | - INR | -100.0% |
2018 Q3 | - INR | -100.0% |
2017 Q1 | - INR | 0.0% |
2017 Q2 | 1.64 Billion INR | 0.0% |
2017 Q3 | - INR | -100.0% |
2017 Q4 | 1.69 Billion INR | 0.0% |
2017 FY | 1.69 Billion INR | 10.92% |
2016 FY | 1.52 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Ajanta Pharma Limited | 10.71 Billion INR | 94.94% |
Amrutanjan Health Care Limited | 783.82 Million INR | 30.861% |
Sigachi Industries Limited | 2.53 Billion INR | 78.591% |
Bal Pharma Limited | 2.51 Billion INR | 78.42% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 76.33% |
Medico Remedies Limited | 438.24 Million INR | -23.658% |
Venus Remedies Limited | 1.39 Billion INR | 61.091% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 86.079% |
Alpa Laboratories Limited | 307.12 Million INR | -76.453% |
Nectar Lifesciences Limited | 11.21 Billion INR | 95.169% |
Shilpa Medicare Limited | 12.93 Billion INR | 95.81% |
Aarti Drugs Limited | 11.5 Billion INR | 95.289% |
Lupin Limited | 96.23 Billion INR | 99.437% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.644% |
Zydus Lifesciences Limited | 71.79 Billion INR | 99.245% |
Windlas Biotech Limited | 1.76 Billion INR | 69.256% |
Suven Life Sciences Limited | 148.62 Million INR | -264.636% |
Eris Lifesciences Limited | 38.26 Billion INR | 98.584% |
Valiant Laboratories Limited | 1.05 Billion INR | 48.791% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 94.939% |
Solara Active Pharma Sciences Limited | 14.14 Billion INR | 96.168% |
Ipca Laboratories Limited | 33.74 Billion INR | 98.394% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 74.302% |
Achyut Healthcare Limited | 2.01 Million INR | -26821.262% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.705% |
Bajaj HealthCare Limited | 4.86 Billion INR | 88.867% |
RPG Life Sciences Limited | 1.38 Billion INR | 60.736% |
Mankind Pharma Limited | 23.87 Billion INR | 97.73% |
Laurus Labs Limited | 42.71 Billion INR | 98.731% |
Piramal Pharma Limited | 74 Billion INR | 99.268% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 53.491% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.34% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 96.67% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 99.168% |
Unichem Laboratories Limited | 8.06 Billion INR | 93.284% |
Sequent Scientific Limited | 8.27 Billion INR | 93.45% |
Novartis India Limited | 1.8 Billion INR | 69.911% |
Wanbury Limited | 3.15 Billion INR | 82.826% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 73.36% |
Wockhardt Limited | 39.87 Billion INR | 98.641% |
Themis Medicare Limited | 1.88 Billion INR | 71.289% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -82.614% |
Jubilant Pharmova Limited | 61.27 Billion INR | 99.116% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 89.54% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.493% |
Divi's Laboratories Limited | 18.99 Billion INR | 97.146% |
NATCO Pharma Limited | 10.53 Billion INR | 94.854% |
Gufic Biosciences Limited | 5.59 Billion INR | 90.322% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 91.437% |
Ind-Swift Limited | 13.45 Billion INR | 95.972% |
Procter & Gamble Health Limited | 2.56 Billion INR | 78.841% |
FDC Limited | 3.7 Billion INR | 85.39% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 81.777% |
Granules India Limited | 22.95 Billion INR | 97.639% |
Medicamen Biotech Limited | 940.36 Million INR | 42.371% |
Alkem Laboratories Limited | 48.6 Billion INR | 98.885% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 85.198% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -87.648% |
Brooks Laboratories Limited | 248.6 Million INR | -117.99% |
Megasoft Limited | 1.85 Billion INR | 70.756% |
ZIM Laboratories Limited | 2.08 Billion INR | 73.955% |
Strides Pharma Science Limited | 37.68 Billion INR | 98.562% |
Neuland Laboratories Limited | 5.49 Billion INR | 90.144% |
Morepen Laboratories Limited | 4.45 Billion INR | 87.849% |
Hikal Limited | 12.99 Billion INR | 95.83% |
Indoco Remedies Limited | 10.34 Billion INR | 94.76% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 93.432% |
Kilitch Drugs (India) Limited | 643.88 Million INR | 15.835% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 72.579% |
Hester Biosciences Limited | 3.59 Billion INR | 84.924% |